KIR2DL1: Killer cell immunoglobulin-like receptor 2DL1
Receptor on natural killer (NK) cells for some HLA-C alleles such as w4 and w6.
- Drugs that act on it: 2
- Approved: 0
- In phases 1 to 3: 2
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on KIR2DL1, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
| Lirilumab | Phase 2 | Innate Pharma | Antibody | InhibitorKiller cell immunoglobulin-like receptor 2DL1 inhibitor | 2 |
| IPH-2101 | Phase 2 | Innate Pharma | Other | InhibitorKiller cell immunoglobulin-like receptor 2DL1 inhibitor | 0 |
| Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN | Lirilumab | Phase 2 | Active, not recruiting | Dana-Farber Cancer Institute | Nov 14, 2017 |
| European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors | Lirilumab | Phase 1 / Phase 2 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | Jun 24, 2016 |
- Keratoconus0.11
- Plasma cell myeloma0.11
- Acute myeloid leukemia0.10
- Myelodysplastic syndrome0.10
- Acute myeloid leukemia by FAB classification0.09
- Breast cancer0.09
- Endometriosis0.08
- B-cell chronic lymphocytic leukemia0.08
- Head and neck squamous cell carcinoma0.07
- Esophageal squamous cell carcinoma0.07
- COVID-190.07
- Cancer0.06
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3712912, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P43626, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets